Developing New Schiff Base Complexes with Pyridine Moiety as Anticancer Agents

This chapter investigated to develop New Schiff Base Complexes with Pyridine Moiety as Anticancer Agents. Cancer can result from abnormal proliferation of any of the different kinds of cells in the body, so there are more than a hundred distinct types of cancer, which can vary substantially in their behavior and response to treatment. The most important issue in cancer pathology is the distinction between benign and malignant tumors. This study searched the anticancer studies of pyridine Schiff base metal complexes from 2015 to 2021. Information was gathered from the selected studies to analyze and highlight the importance of anticancer agents. A total of sixty six full-length articles on the subject were examined, the results were summarized, and the activity against different cell types was given as IC50 values or inhibition percentages. On the critical assessment, we found that compared to Schiff base ligand, the metal complexes exhibited excellent activity towards various cancer cell lines (including MCF-7, HeLa, HCT-116, Hepa-2). This chapter discovered that the metal complexes were more potent than the Schiff base ligands. We conclude that this article will aid researchers in developing new Schiff base complexes with pyridine moiety as anticancer agents.